Hepatocyte growth factor, but not vascular endothelial growth factor, attenuates angiotensin II-induced endothelial progenitor cell senescence

Hypertension

Volumn 53, Issue 1, 2009, Pages 77-82

  Sanada, Fumihiro ^a,b   Taniyama, Yoshiaki ^a   Azuma, Junya ^a   Iekushi, Kazuma ^a   Dosaka, Norio ^a   Yokoi, Toyohiko ^a   Koibuchi, Nobutaka ^c   Kusunoki, Hiroshi ^a   Aizawa, Yoshifusa ^b   Morishita, Ryuichi ^a  

^a OSAKA UNIVERSITY   (Japan)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

Angiotensin II; EPC; HGF; Oxidative stress; Senescence; VEGF

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANGIOTENSIN II; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; RAC1 PROTEIN; SCATTER FACTOR; SUPEROXIDE DISMUTASE; VASCULOTROPIN; WORTMANNIN; PHOSPHATIDYLINOSITOL 3,4,5-TRIPHOSPHATE; POLYPHOSPHOINOSITIDE; RAC1 PROTEIN, RAT; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASOCONSTRICTOR AGENT;

ARTICLE; BONE MARROW TRANSPLANTATION; DRUG MEGADOSE; ENDOTHELIUM CELL; LIMB ISCHEMIA; LOW DRUG DOSE; NEOVASCULARIZATION (PATHOLOGY); OXIDATIVE STRESS; PRIORITY JOURNAL; SENESCENCE; STEM CELL; TRANSGENIC MOUSE; WESTERN BLOTTING; ANGIOGENESIS; ANIMAL; C57BL MOUSE; CELL AGING; CELL CULTURE; CYTOLOGY; DISEASE MODEL; DRUG EFFECT; GENETICS; HINDLIMB; HUMAN; ISCHEMIA; MESENCHYMAL STEM CELL; METABOLISM; MOUSE; NUDE MOUSE; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ANGIOTENSIN II; ANIMALS; CELL AGING; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; HEPATOCYTE GROWTH FACTOR; HINDLIMB; HUMANS; ISCHEMIA; MESENCHYMAL STEM CELLS; MICE; MICE, INBRED C57BL; MICE, NUDE; MICE, TRANSGENIC; NEOVASCULARIZATION, PHYSIOLOGIC; OXIDATIVE STRESS; PHOSPHATIDYLINOSITOL PHOSPHATES; RAC1 GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASOCONSTRICTOR AGENTS;

EID: 58149398624     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.108.120725     Document Type: Article

References (32)

1. Second European consensus document on chronic critical leg ischemia. Circulation. 1991;84:IV1-IV26.
2. Baumgartner I, Pieczek A, Manor O, Blair R, Kearney M, Walsh K, Isner JM. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation. 1998;97:1114-1123.
3. Rajagopalan S, Mohler E III, Lederman RJ, Saucedo J, Mendelsohn FO, Olin J, Blebea J, Goldman C, Trachtenberg JD, Pressler M, Rasmussen H, Annex BH, Hirsch AT. Regional angiogenesis with vascular endothelial growth factor (VEGF) in peripheral arterial disease: design of the RAVE Trial. Am Heart J. 2003;145:1114-1118.
4. Powell RJ, Simons M, Mendelsohn FO, Daniel G, Henry TD, Koga M, Morishita R, Annex BH. Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation. 2008;118:58-65.
5. Vasa M, Fichtischerer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM, Dimmeler S. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res. 2001;89:E1-E7.
6. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003;348:593-600.
7. Yu Y, Fukuda N, Yao EH, Matsumoto T, Kobayashi N, Suzuki R, Tahira Y, Ueno T, Matsumoto K. Effects of an ARB on endothelial progenitor cell function and cardiovascular oxidation in hypertension. Am J Hypertens. 2008;21:72-77.
8. Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ, Jacobowitz GR, Levine JP, Gurtner GC. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation. 2002;106:2781-2786.
9. Iekushi K, Taniyama Y, Azuma J, Katsuragi N, Dosaka N, Sanada F, Koibuchi N, Nagao K, Ogihara T, Morishita R. Novel mechanisms of valsartan on the treatment of acute myocardial infarction through inhibition of the antiadhesion molecule periostin. Hypertension. 2007;49: 1409-1414.
10. Yao EH, Fukuda N, Matsumoto T, Kobayashi N, Katakawa M, Yamamoto C, Tsunemi A, Suzuki R, Ueno T, Matsumoto K. Losartan improves the impaired function of endothelial progenitor cells in hypertension via an antioxidant effect. Hypertens Res. 2007;30:1119-1128.
11. Imanishi T, Hano T, Nishio I. Angiotensin II accelerates endothelial progenitor cell senescence through induction of oxidative stress. J Hypertens. 2005;23:97-104.
12. Chen J, Goligorsky MS. Premature senescence of endothelial cells: Methusaleh's dilemma. Am J Physiol Heart Circ Physiol. 2006;290: H1729-H1739.
13. Imanishi T, Hano T, Nishio I. Angiotensin II potentiates vascular endothelial growth factor-induced proliferation and network formation of endothelial progenitor cells. Hypertens Res. 2004;27:101-108.
14. Garrett TA, Van Buul JD, Burridge K, VEGF-induced Rac1 activation in endothelial cells is regulated by the guanine nucleotide exchange factor Vav2. Exp Cell Res. 2007;313:3285-3297.
15. Taniyama Y, Ushio-Fukai M, Hitomi H, Rocic P, Kingsley MJ, Pfahnl C, Weber DS, Alexander RW, Griendling KK. Role of p38 MAPK and MAPKAPK-2 in angiotensin II-induced Akt activation in vascular smooth muscle cells. Am J Physiol Cell Physiol. 2004;287:C494-C499.
16. Abid MR, Spokes KC, Shih SC, Aird WC. NADPH oxidase activity selectively modulates vascular endothelial growth factor signaling pathways. J Biol Chem. 2007;282:35373-35385.
17. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275:964-967.
18. Lunde K, Solheim S, Aakhus S, Arnesen H, Abdelnoor M, Egeland T, Endresen K, Ilebekk A, Mangschau A, Fjeld JG, Smith HJ, Taraldsrud E, Grogaard HK, Bjornerheim R, Brekke M, Muller C, Hopp E, Ragnarsson A. Brinchmann JE, Forfang K. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med. 2006; 355:1199-1209.
19. Feugier P, Jo DY, Shieh JH, MacKenzie KL, Rafii S, Crystal RG, Moore MA. Ex vivo expansion of stem and progenitor cells in co-culture of mobilized peripheral blood CD34+ cells on human endothelium transfected with adenovectors expressing thrombopoietin, c-kit ligand, and Flt-3 ligand. J Hematother Stem Cell Res. 2002;11:127-138.
20. Assmus B, Urbich C, Aicher A, Hofmann WK, Haendeler J, Rossig L, Spyridopoulos I, Zeiher AM, Dimmeler S. HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ Res. 2003;92:1049-1055.
21. Miyauchi H, Minamino T, Tateno K, Kunieda T, Toko H, Komuro I. Akt negatively regulates the in vitro lifespan of human endothelial cells via a p53/p21-dependent pathway. EMBO J. 2004;23:212-220.
22. Min JK, Lee YM, Kim JH, Kim YM, Kim SW, Lee SY, Gho YS, Oh GT, Kwon YG. Hepatocyte growth factor suppresses vascular endothelial growth factor-induced expression of endothelial ICAM-1 and VCAM-1 by inhibiting the nuclear factor-kappaB pathway. Circ Res. 2005;96: 300-307.
23. Abid MR, Schoots IG, Spokes KC, Wu SQ, Mawhinney C, Aird WC. Vascular endothelial growth factor-mediated induction of manganese superoxide dismutase occurs through redox-dependent regulation of forkhead and IkappaB/NF-kappaB. J Biol Chem. 2004;279: 44030-44038.
24. Reinders ME, Sho M, Izawa A, Wang P, Mukhopadhyay D, Koss KE, Geehan CS, Luster AD, Sayegh MH, Briscoe DM. Proinflammatory functions of vascular endothelial growth factor in alloimmunity. J Clin Invest. 2003;112:1655-1665.
25. Ushio-Fukai M. VEGF signaling through NADPH oxidase-derived ROS. Antioxid Redox Signal. 2007;9:731-739.
26. Lucerna M, Zernecke A, de Nooijer R, de Jager SC, Bot I, van der Lans C, Kholova I, Liehn EA, van Berkel TJ, Yla-Herttuala S, Weber C, Biessen EA. Vascular endothelial growth factor-A induces plaque expansion in ApoE knock-out mice by promoting de novo leukocyte recruitment. Blood. 2007;109:122-129.
27. Gong R, Rifai A, Dworkin LD. Anti-inflammatory effect of hepatocyte growth factor in chronic kidney disease: targeting the inflamed vascular endothelium. J Am Soc Nephrol. 2006;17:2464-2473.
28. Li H, Jiang T, Lin Y, Zhao Z, Zhang N. HGF protects rat mesangial cells from high-glucose-mediated oxidative stress. Am J Nephrol. 2006;26: 519-530.
29. Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, Griendling KK. Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ Res. 2002;91:406-413.
30. Ushio-Fukai M, Tang Y, Fukai T, Dikalov SI, Ma Y, Fujimoto M, Quinn MT, Pagano PJ, Johnson C, Alexander RW. Novel role of gp91(phox)-containing NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis. Circ Res. 2002;91:1160-1167.
31. Tojo T, Ushio-Fukai M, Yamaoka-Tojo M, Ikeda S, Patrushev N, Alexander RW. Role of gp91phox (Nox2)-containing NAD(P)H oxidase in angiogenesis in response to hindlimb ischemia. Circulation. 2005;111: 2347-2355.
32. M, Djonov VG, Schnell C, Tschanz SA, Martiny-Baron G, Schenk U, Wood J, Burri PH, Hubbell JA, Zisch AH. Cell-demanded liberation of VEGF121 from fibrin implants induces local and controlled blood vessel growth. Circ Res. 2004;94:1124-1132.